A quantitative systems pharmacology consortium approach to managing immunogenicity of therapeutic proteins

Immunogenicity is a major challenge in drug development and patient care. Currently, most efforts are dedicated to the elimination of the unwanted immune responses through T‐cell epitope prediction and protein engineering. However, because it is unlikely that this approach will lead to complete eradication of immunogenicity, we propose that quantitative systems pharmacology models should be developed to predict and manage immunogenicity. The potential impact of such a mechanistic model‐based approach is precedented by applications of physiologically‐based pharmacokinetics.